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B cell growth-promoting activities have recently been described by a  number 
of investigators  in  both  mouse and  human  models.  These activities have been 
identified  in  mitogen-induced  culture  supernatants  of normal  cells  (1,  2),  cell 
lines (3-5), and hybridomas (6-13). These B cell growth factor (BCGF) ~ activities 
have been detected and measured in a number of different assays. These include 
the measurement of the proliferation of normal B  cells after costimulation with 
anti-Ig (6,  7,  12,  13) or mitogens (2,  9,  10,  12,  14),  or direct  stimulation  of B 
cells from B  cell lymphomas (1-3,  11).  Since the assay systems and the sources 
of the lymphokine activities have varied between individual  investigators, it has 
not  been  possible  to  conclude  whether  one  or  more  different  factors  were 
responsible for B cell proliferation. 
Some  of  us  recently  described  (3)  a  growth  factor  from  the  Dennert  line 
C.C3.11.75,  termed  (DL)BCGF, 2 which  maintained  the  growth  of the  in  vivo 
BCL~  tumor  line and appeared  to bind  to receptors  on  the  tumor cells (3).  In 
our early attempts to characterize this material, it was clear that it was unusually 
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Abbreviations used in this paper:  BCGF, B cell growth  factor;  DXS, dextran sulfate; Con A, 
concanavalin  A;  IFN,  interferon;  IL-2,  interleukin  2;  [l~sI]UdR, [I~I]iododeoxy  uridine;  LPS, 
lipopolysaccharide; MAb, monoclonal antibody; pl, isoelectric point; PMA, phorbol myristate acetate; 
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2 Factor preparation  nomenclature:  Since the possible relationships of different  factors are un- 
known, we have designated factor preparations  other than  IL-1 and IL-2 by their activity (e.g., a 
preparation  that has activity in a B cell growth assay is designated BCGF), preceded in parentheses 
by an indication of the cell line source of the relevant hybridoma (e.g., BCGF from the DL line is 
designated (DL)BCGF). 
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labile to extremes of heat and to low pH (S. Swain, J.  Watson, R. Booth, and R. 
Dutton,  unpublished  results) and did not have the chromatographic properties 
reported for several other murine BCGF preparations (5, 6,  13). 
In particular,  the (EL4)BCGF reported by Howard and colleagues (6), when 
assayed on anti-#-induced  B  cells was  more stable  with a  molecular weight of 
-~ 18,000 by gel filtration analysis, whereas (DL)BCGF gave low recoveries and 
activity  in  the  50,000-70,000  mol  wt  fractions  (S.  Swain,  G.  Wetzel,  and  R. 
Dutton,  unpublished  results).  We  therefore undertook a  series of experiments 
to compare the activities of (DL)BCGF and two other BCGF preparations (EL4 
and FS6.14.13) using three assay systems. The results of these experiments reveal 
the existence of two distinct classes  of BCGF that  can be distinguished  by the 
assays in which they can be measured.  We have provisionally designated these 
two classes as BCGF I  and BCGF II. The data suggest that BCGF I  and BCGF 
II are active on B cells in different stages of differentiation and/or that they are 
specific for two subsets of B cells. 
Materials and Methods 
Animals 
Mice of strains CBA/N, DBA/2J, C57BL/6J, BALB/c, and BALB/cByJ were raised 
in our own colony from breeding pairs originally obtained from The Jackson Laboratory, 
Bar Harbor, ME. BALB/cKe breeding pairs were obtained from the Salk Institute, La 
Jolla, CA. All F1 hybrid mice were bred in our own colony. 
Monoctonal  Antibodies (MAb) 
The cell line making anti-Thy-l.2, F7D5 was a kind gift from Dr. Phil Lake, then at 
University College, London, England. The line making anti-Thy-l.2, H0.13.4 was a kind 
gift of Dr. Ann Marshak-Rothstein,  Massachusetts Institute of Technology, Cambridge, 
MA, and the  line making anti-Lyt-2.2, AD4.15  was a  kind gift of Dr. Michael Bevan, 
Research Institute of Scripps Clinic, La Jolla, CA. All antibodies were from ascites taken 
from Pristane-injected mice inoculated with tumor cells. 
Tumor Lines 
The in vivo-passed BCL tumor was a kind gift of Dr. Sam Strober, Stanford University 
School  of Medicine,  Stanford,  CA  (15).  The  tumor  was  maintained  by  intravenous 
injection of 106 cells from the spleen of tumor-bearing mice 6-10 wk after inoculation. 
BALB/cByJ or BALB/cKe were used interchangeably as tumor-bearing animals. Palpable 
tumors appeared in these mice 4 wk after injection. Tumor cells were used in proliferation 
experiments at any time between 1 wk after the appearance of  tumors (5 wk post-injection) 
and the death of the animals (8-10 wk). BCL1 cells were B cells that expressed IgM (16). 
Factor Preparations 
Sources of BCGF.  (DL)BCGF was obtained as described previously (3,  17) from the 
supernatants of the C.C3.11.75  line either after stimulation with non-T cells,  after no 
stimulation, or after stimulation with interleukin 2 (IL-2)-containing supernatants (3). The 
preparations used in these studies were all extensively characterized. They contained no 
IL-I or IL-2 (17) and many of them did not contain interferon (IFN) (J. Klein, unpublished 
results).  Most  preparations did  contain (DL) T  cell-replacing factor (TRF), but  their 
activity in the proliferation assays was not related to their content of TRF (3). 
(EL4)BCGF was prepared from phorbol myristate acetate (PMA)-stimulated EL4 thy- 
moma cells as detailed previously (6,  18). The BCGF was separated from IL-2 and TRF 
in these same supernatants  by phenyI-Sepharose column chromatography as described 824  TWO  FUNCTIONALLY DISTINCT B CELL  GROWTH  FACTORS 
elsewhere (18). The final preparation contained no IL-1, IL-2, TRF, or IFN (18,  19; J. 
Klein, unpublished results). 
(FS6)BCGF was an ammonium sulfate-concentrated preparation from concanavalin A 
(Con A)-stimulated FS6.14.13  hybridoma cells as described elsewhere (20).  This super- 
natant was previously reported to have BCGF activity (21, 22).  The supernatants used in 
these experiments contain large amounts of IL-2 but do not contain TRF or IFN. 
(B151K12)BCGF  was a  kind  gift of Dr.  K.  Takatsu,  Osaka  University, Japan.  The 
preparation used in these experiments was constitutive supernatant from the B 151 K 12 
hybridoma prepared as described previously (23). This supernatant contains TRF activity 
in a TRF assay (K. Takatsu, unpublished results), in addition to its BCGF activity (3), but 
not  IFN  (J.  Klein,  unpublished  results).  Bulk  EL4  supernatant  was  the  unseparated 
supernatant of PMA-stimulated cultures and is known to contain IL-2, TRF, and BCGF 
activities (6,  19). 
BW.Mls supernatants were obtained by Con A  stimulation of a  hybridoma made by 
fusing BW5147  and short-term in vitro Mls-specific T  cells (CBA/CaJ stimulated with 
CBA/J)  (T.  Beardsley  and  S.  Swain,  unpublished  results).  Supernatants  made  from 
subclones of the original are found that are respectively enriched for either IL-2 or BCGF 
(S. Swain, unpublished results). An ammonium sulfate concentrate rich in BCGF activity 
but  with  little  IL-2 was used  in  the  BCGF assays.  No  TRF or  IFN  is found  in  these 
supernatants. 
Sources oflL2.  IL-2jw was highly purified from Con A supernatant of normal spleen 
cells by chromatography and isoelectric focusing as described previously (24).  IL-2EL, was 
prepared from the same unseparated EL4 supernatants that were the source of(EL4)BCGF. 
The IL-2-containing fractions were taken after phenyl-Sepharose chromatography. They 
contained no BCGF or TRF (18,  19). I L2Bw.M~s was obtained from supernatants of certain 
clones of BW.MIs, described above, that produced high amounts of IL-2 and very little 
BCGF. 
Anti-Ig Sources 
Anti-Ig was either selected goat anti-mouse ~-chain (whole affinity-purified Ig (6)  or 
F(ab')2 fragments prepared from rabbit antibodies to Ig (7,  21).  Anti-~ or anti-Ig was 
generally used in concentrations of 2-10 #g in synergy with BCGF. 
Mitogens 
Lipopolysaccharide (LPS) was obtained from Escherichia coli 055:B5  by the Westphal 
technique  and  was  purchased  from  Difco  Laboratories,  Detroit,  MI.  Dextran  sulfate 
(DXS) was a sodium salt, 17% sulfur, 500,000 mol wt (Gibco Laboratories, Grand Island, 
NY). 
ASSOyS 
Normal B Cells  B cells were prepared as described previously (3, 6) by slight modifi- 
cation of the procedure described previously (20, 25).  Mice were injected at days -3 and 
-1  or at day -2 with 0.06 ml antithymocyte serum (Mirobiological Associates, Walkers- 
ville,  MD). Spleens of such mice were removed and treated with a cocktail of anti-T cell 
MAb including  two anti-Thy-l.2, anti-Lyt-l.2, and/or  anti-Lyt-2.2, and in  some cases 
MK2.2  (20).  T-depleted  spleens  were  passaged  through  Sephadex  G-10.  Cells  were 
4  5  cultured in triplicate at concentrations ranging from 2  ×  10  to  1 ×  10  per well with 
1251  125  $  serial dilutions of factors or other stimuli.  [  I]iododeoxy uridine  ([  I]UdR) or [ H]- 
thymidine was added for the last 6 h of a 72 h culture and the degree of proliferation was 
assessed by determining  incorporation  of the  radiolabel.  Geometric means and  SE of 
triplicate cultures were determined and stimulation indices were obtained by the ratio of 
test counts per minute divided by control counts per minute. For anti-Ig-costimulated B 
cell proliferation, anti-Ig at 2-10 #g/ml was added to normal B cells.  For DXS-costimu- 
lated proliferation, DXS at 50 ~g/ml was added to B cells. 
BCLI Proliferation.  Spleens were removed from mice bearing the BCL~ tumor (recov- 
eries varied from 8 ×  l0 s to 1.3 ×  109 per mouse), treated in vitro with two Thy-l.2 MAb SWAIN ET  AL.  825 
and anti-Lyt-2.2 MAb plus complement as for normal B cells. In many cases cells were 
subsequently passaged on Sephadex G-10. The resulting cell population was resuspended 
at 5 ×  105/ml, and 5 ×  104 cells were added to microtiter cultures (3596; Costar, Data 
Packaging, Cambridge, MA).  Factors or other stimuli were added in  10- or 20-~1 vol. 
Proliferation was determined after 72 h as described above for normal B cells. 
Determination of Cell Cycle State.  Two-color flow cytofluorometry was used to simulta- 
neously determine DNA content and RNA content of individual cells. A  minimum of 
10,000  cells were stained with acridine orange as described in detail elsewhere? The 
fluorescence signals of each cell were optically separated into two wavelength bands: green 
(510-550 nm) corresponding to DNA content, and red (>630 nm) corresponding to RNA 
content.  This  was  possible  since  AO  interacts  monomerically with  DNA,  yielding a 
characteristic fluorescence maximum at 530 rim, but interacts multimerically with single- 
stranded RNA and shows a  fluorescence maximum at 640 nm. This technique of cell 
cycle analysis has the advantage that resting Go cells can be distinguished from activated 
G1 phase cells. 
Results 
(DL)BCGF Does Not Synergize with Anti-I~ for the Proliferation  of Normal or BCL1 
Tumor B Cells.  The proliferation of highly T-depleted B cells to (EL4)BCGF is 
dependent, at low cell numbers per culture, on the presence of anti-Ig of either 
goat origin (6) or F(ab')2 fragments from rabbits (22). (DL)BCGF was tested in 
four separate laboratories for its ability to synergize with anti-Ig preparations in 
this type of assay. The results of two representative experiments are illustrated 
in Fig.  1. 
Fig.  1A shows that although phenyl Sepharose-purified (non-IL-2-containing) 
(EL4)BCGF gives very good proliferation of normal  B  cells in the presence  of 
anti-#, the addition of anti-# did not enhance (DL)BCGF-dependent proliferation. 
Fig.  1 B shows a  similar experiment comparing (DL)BCGF with factors present 
in concentrated supernatants of FS6.14.13.  This second experiment was run in 
the presence of saturating levels of IL-1 from P388D1 (25) as well as anti-Ig, thus 
ensuring that IL-1 limitation was not contributing to the failure of DL superna- 
tants to support  proliferation.  The third panel  (Fig.  1 C)  shows that the  same 
(DL)BCGF  preparation  very  actively  supports  the  proliferation  of the  BCL~ 
tumor line and that  the addition of anti-#  to this assay does not enhance  the 
proliferation induced by (DL)BCGF. 
(EL4) BCGF and (FS6)BCGF Do Not Support Proliferation  of BCL1  Cells.  (EL4) 
and (FS6)BCGF were next tested for their abilities to support the proliferation 
of the BCL1 tumor. As shown in Fig. 2, neither of these factors supports BCL~ 
proliferation, in marked contrast to (DL)BCGF. 
(DL)BCGF Causes the Proliferation  of Normal B Cells Costimulated  With DXS.  In 
an earlier study (3), we found that (DL)BCGF had a  direct effect on normal B 
cells. The amount of proliferation seen in these normal B cells was small, however, 
and we suggested that it might be acting on a  small subpopulation of already 
activated normal B cells that might be in a  similar stage of development as the 
BCL1  tumor cells (3).  We have recently found that up to 90%  of BCL1  tumor 
cells isolated from BALB/c mice are cycling cells with a large proportion in G1, 
whereas normal B cells are >95%  resting cells in Go (Table  I). Thus we felt it 
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FIGURE  l.  Activities of BCGF preparations costimulated with anti-Ig. (DL)BCGF was com- 
pared with two BCGF previously found to costimulate proliferation of B cells induced with 
anti-lg. (A) 5 ×  104 purified B cells were incubated alone (open symbols) or in the presence of 
5  /~g/ml purified  goat  anti-mouse  Ig (closed  symbols);  with  (DL)BCGF ((3, @) or phenyl- 
Sepharose purified (EL4)BCGF (A, A) titrated into these cultures. [SH]TdR was added for the 
last 6 h of a 72-h culture period. (B) 5 ×  104 purified B cells were mixed with 10% constitutive 
supernatant of P388DI cells containing IL-1 and incubated with 5/~g/ml F(ab')~ fragments of 
purified rabbit anti-mouse lg sera.  (O) (DL)BCGF; concentrated supernatants  of FS6.14.13 
(A) were titrated into these cultures. Incorporation was determined as in A. (C) 5 ×  104 purified 
BCLI B cells were incubated alone ((3) or with 5 ttg/mt purified F(ab')2 fragments of rabbit 
anti-mouse u-chain sera (Q); (DL)BCGF was titrated into these cultures. [125I]UdR was added 
for the last 6 h of a 72-h culture. 
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FIGURE 2.  Activities of BCGF preparations  in  BCLj  B  cell proliferation.  (DL)BCGF (0), 
(FS6)BCGF (A),  and  (EL4)BCGF (V)  were  titrated  into cultures  of 5  ×  104  BCLt  B  cells. 
['25I]UdR was added for the last 6 h of a 72-h culture. 
might  be  possible  to  induce  a  much  larger  response  of  normal  B  cells  to 
(DL)BCGF in the presence of a costimulating agent that could stimulate a Go to 
G~ transition of some of the normal B cells. The data in Tables II and III show 
our success  in  developing a  costimulator assay with  normal  B  cells and  DXS. 
DXS stimulates a  portion of B cells to go from Go to G~ states (Table I), but by 
itself is  quite  ineffective in  stimulating normal  B  cell  proliferation (Table  II). SWAIN  ET  AL. 
TABLE  I 
Cycle Analysis of Stimulated and Unstimulated B Cells 
Percent cells 
Go  Gl  S,G2,M 
Normal B*  96.5  2.1  1.4 
DXS-stimulated B*  87.7  7.6  2.4 
BCLI B Cells*  8.9  88.1  3.0 
This table is one of three similar experiments. 
* Normal B and  BCL~ B were obtained as indicated in  Materials and 
Methods. 
* Bulk cultures of 2 ×  10~/ml B cells were stimulated with 50 ug]ml of 
DXS for 40 h. 
TAnLE  II 
Activity of (DL)BCGF on Normal B Cells in Costimulation With DXS 
827 
Additions 
Normal B cells  BCL~ cells 
cpm/culture  SI  cpm/culture  SI 
None 
DL supernatant 
DXS 
DXS + DL supernatant 
LPS 
181  1.00  163  1.00 
2%  376  2.08  1,372  8.42 
0.4%  258  1.43  935  5.74 
0.08%  213  1.18  504  3.09 
50 ~,g/ml  499  2.76  278  1.71 
2%  3,368  18.61  934  5.73 
0.4%  2,109  11.65  475  2.91 
0.08%  1,164  6.43  262  1.61 
50 ug/ml  4,004  22.12 
Purified normal B or BCLt cells at 5 x  104/well were incubated with or without 50 #g/ml of DXS 
and DL supernatant containing (DL)BCGF was added at doses ranging from 2 to 0.08%. Incorpo- 
ration was determined by adding [125I]UdR during the last 6 h of a  72-h culture. SI, stimulation 
indice. SI equal cpm in stimulated cultures divided by CPM in unstimulated cultures. 
The  addition of (DL)BCGF to DXS-costimulated B  cells causes a  very impressive 
synergy in B  cell proliferation (Table II and Fig. 3). As might be predicted, DXS 
has  no  effect  on  the  already high  proliferation  of BCL~  B  cells (Table  II).  It 
seems then  that  DXS  has  an  effect  on  all or a  subset  of normal  B  cells which 
causes them to become responsive to (DL)BCGF. 
(EL4)BCGF Does Not Have Activity in the DXS-B Cell Costimulator Assay.  Next we 
tested whether  (EL4)BCGF,  which had  activity in the anti-# costimulator assay, 
would also synergize with  DXS  in  normal  B  cell proliferation.  (EL4)BCGF  did 
not synergize with  DXS for the proliferative response of either unstimulated or 
DXS-activated  normal  B  cells (Fig.  3).  A  further  comparison  of the  effects  of 
different sources of growth  factors, including the  unfractionated  PMA-induced 
supernatant  from  the  EL4  line,  Con  A-induced  FS6.14.13  supernatants,  the 
B151K12  line (23), and our BW.MIs hybridoma  line, are shown in Table  III. 
A  clear pattern  indicating two  different  BCGF  activities emerges  from  these 828  TWO  FUNCTIONALLY  DISTINCT  B  CELL  GROWTH  FACTORS 
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FIGURE 3.  Activities of BCGF preparations on DXS-costimulated normal B cells. Purified B 
cells were cultured at 5  x  104/well alone (A, open symbols) or in the presence of 50 #g/ml 
DXS (B, closed symbols). The (DL)BCGF (O, Q) and (EL4)BCGF (A, &) preparations tested in 
Figs.  1 and 2 were titrated into such cultures. [l~sI]UdR was added for the last 6 h of a  72-h 
culture. 
experiments.  We will designate  those BCGF activities that  score in  the anti-Ig 
costimulator assays and whose prototype is (EL4)BCGF as tentatively belonging 
to the BCGF I class, and those which score in the BCLI proliferation assay and 
costimulate  with  DXS  in  normal  B  cell  proliferation,  whose  prototype  is 
(DL)BCGF, as belonging to the BCGF II class. A summary of the activities of a 
variety of different factor preparations in these assays is contained in Table IV. 
In addition to (EL4)BCGF and FS6, BCGF I activity is found in unseparated EL4 
supernatants.  BCGF II activity is found in supernatants we have tested from the 
BW.MIs line, B 151 K 12 hybridoma, and bulk EL4 supernatants. 
Discussion 
The testing of a variety of sources of BCGF activities in a panel of different B 
cell proliferation assays has allowed us to describe two distinct classes of BCGF 
whose prototypes are (EL4)BCGF and (DL)BCGF. We have provisionally named 
these two classes BCGF I and BCGF II, respectively. BCGF I causes the prolif- 
eration of normal B cells that have been costimulated with anti-Ig but does not 
costimulate proliferation with DXS or stimulate proliferation of the BCL~ tumor 
line. In a reciprocal fashion, BCGF II has no enhancing effect on the proliferation 
of normal B cells plus anti-Ig, but is very effective at costimulating in the presence 
of DXS and at stimulating the proliferation of the BCL1 tumor line. Supernatants 
of various cell  lines and  hybridomas  have  been  tested for these activities and 
many have one or both of them. 
Two possible interpretations  of the significance of these results for normal B 
cell  responses  can  be  considered.  It  is  possible  either  that  these  two  growth 
factors have effects on different stages of the differentiation of one subset of B 
cells or that  they act on two separate lineages of B cells. This  issue cannot be 
resolved from the data available, but it is worthwhile considering what we know 
about the individual  assays and reagents for a  background  to approaching  this 
question. SWAIN  ET  AL. 
TABLE  III 
Comparisons of BCGF in Different Proliferation Assays 
829 
Assay  Expt.  Supernatant  cpm/culture  Stimulation 
source  index 
Anti-# Induced Normal B  1  None  230  1.00 
FS6.14.13*  10,000  43.48 
DL*  110  0.48 
2  None  1,320  1.00 
EL4  |  22,319  16.91 
DL*  2,000  1.52 
DXS-Induced Normal B  1 
BCLt 
None  393  1.00 
EL4 !  524  1.33 
DL*  5,143  13.09 
None  1,443  1.00 
EL4  |  2,692  1.87 
DL*  9,333  6.47 
FS6.14.13"  3,786  2.61 
B151 t  16,395  11.36 
None  1,545  1.00 
EL4 unseparated'  6,518  4.22 
DL*  6,004  3.89 
BW.Mls**  8,763  5.67 
1  None  263  1.00 
DL*  4,665  17.74 
El4  i  402  1.53 
2  None  364  1.00 
DL  t  6,569  18.05 
El4  !  863  2.37 
FS6.14.13*  647  1.77 
B151  3,760  10.33 
3  None  1,237  1.00 
EL4 unseparated'  6,828  5.52 
DL*  7,977  6.45 
BW.MIs**  6,074  4.91 
BCGF preparations were screened in three proliferation assays. Factor preparations were added 
over a range of 10-0.016% per culture. Peak proliferation is shown and was usually found at the 
10 or 2% factor addition. Factor preparations listed below have all been tested in at least three 
such assays with similar results. 
* FS6.14.13 was a 50x ammonium sulfate concentrate of a Con A-induced supernatant. 
* DL supernatant from one batch of DL. Other batches gave similar results. 
0 EL4 was purified BCGF separated from EL4 supernatant, as described in Materials and Methods. 
I B 151 was a 3 x  concentrated supernatant from the B 151K 12 line, a kind gift of Dr. K. Takatsu. 
'  "EL4 unseparated" was unseparated PMA-induced supernatant of the EL4 line. 
** BW.MIs was the concentrated supernatant of the Con  A-induced BW.MIs line as described in 
Materials and Methods. 
The  anti-Ig  synergy assay  and  the  BCGF  I  used  in  this  assay  have  been 
extensively characterized (6,  18).  It appears  that anti-Ig by itself causes a  size 
increase in the vast majority of B cells but that only about half of these B cells 
activated with anti-# go on to proliferate in response to BCGF I (26). Preliminary 
data show that anti-Ig and BCGF  I  must be present very early in the culture, 
from 0  to  12  h  (27).  It has been suggested that anti-Ig is responsible for the 830  TWO  FUNCTIONALLY  DISTINCT  B  CELL  GROWTH  FACTORS 
TABLE  IV 
Summary of Activities of Factor Preparations in B Cell Proliferation Assays 
DXS-  Anti-# 
induced  induced 
Factor  BCLI  normal B  normal B  BCGF type 
preparation  proliferation  prolifer-  prolifer- 
ation  ation 
(EL4)BCGF  -  -  ++++  I 
(FS6)BCGF  -  -  ++++  I 
(DL)BCGF  ++++  ++++  -  II 
(BI51)BCGF  +++  +++  -  II 
(BW.MIs)BCGF  ++  ++  -  II 
EL~ unseparated  +++  +++  +++  I and II 
Con A supernatant  -  -  -  None 
I L2 purified  -  -  -  None 
(multiple) 
BCGF activities were purified or obtained as described in Materials and Methods. 
"EL4 unseparated" was unseparated PMA-induced supernatant of EL4 line. Con 
A  supernatants were  obtained  by  24-h  stimulation of whole  spleen.  Multiple 
purified IL-2 were obtained from Con A supernatant and from EL4 supernatant 
from the human Jurkat line; unpurified IL-2 from BW.MIs supernatants. 
transition of resting B cells from Go to G~ and that BCGF I may have an effect 
early in G~ phase. Completion of the anti-Ig-driven cell cycle requires yet a third 
stimulus, provided by the monokine IL-1, which appears to act at a  later point 
in G~, driving the cells to enter S phase (27, 28). The resting B cells that respond 
to the later parts of this sequence are absent from the spleens of mice with the 
X-linked CBA/N defect (xid).  4 BCGF I from EL4 has been partially characterized 
biochemicaily. It has an apparent molecular weight of 18,000  by gel filtration 
(6),  11,000 and 14,000 by sodium dodecyl sulfate-polyacrylamide  electrophoresis 
(18),  and isoelectric points (pI) of 6.4-6.7  and  7.4-7.6  (18).  A  factor that has 
activity on human B cells in costimulation with anti-t~ and with chromatographic 
properties similar to those of murine (EL4)BCGF has been recently described by 
Okada  et  al.  (11).  When  the  requirements  to  drive  anti-Ig-induced  B  cells 
through both proliferation and differentiation to antibody formation are studied, 
at least two factors, in addition to (EL4)BCGF and IL-1, are required that can be 
provided by the B 15K 12 hybridoma supernatants and by a pI 4.5 component of 
EL4 supernatant (19). Since the B15K12  supernatants contain BCGF II activity 
(this paper), it is possible that one role of this supernatant is to provide a  late- 
acting growth factor. Consistent with this notion, it has previously been observed 
that B15K12  supernatants enhance anti-Ig-induced BCGF  I-dependent prolif- 
eration and increase cell recoveries (19). 
In  contrast  to  the  BCGF  I  assay,  the  costimulation  of DXS  and  BCGF  II 
described here has not yet been extensively studied. DXS was originally described 
as a polyclonal B cell activator, thought to be particularly active on immature B 
cells (29). When the frequency of B cells able to initiate clonal growth was studied 
4 Howard,  M., T. Malek, J. Ansel, W. Kell, D. Cohen, K. Nakanishi, B. Johnson, and W. E. Paul. 
Production  of B  cell glowth  factor  by antigen-stimulated Lyt-I ÷ 2- T  lymphocytes. Manuscript in 
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by Wetzel and Kettman (30) in  limiting dilution, there was a  synergy between 
LPS and DXS such that together they could induce virtually 100% of all B cells 
to form clones, whereas LPS alone induced 1.5% and DXS alone induced 0.1- 
1% (30).  In recent experience, DXS induces 5-40%  of cells in bulk cultures of 
normal splenic B cells to enter G~ phase during the first 48  h  of culture (this 
paper),  but  only a  small  amount  of division  occurs without added  factors,  a 
situation similar to that discussed above for anti-# stimulation. The number of 
GI phase cells found depends largely on the cell density at which the purified B 
cells are stimulated: at high cell densities (5  ×  105/ml),  large number of cells 
enter G1 (up tO 40%), while at lower cell densities (1-2 ×  10~), many fewer cells 
are driven from Go to  GI  (5-20%)  (G.  D.  Wetzel and S.  Swain,  unpublished 
results). This may reflect a  requirement for accessary cells for this transition, 
similar to results found when the effects of LPS stimulation on the B cell cycle 
are analyzed (31). 
The BCL~ proliferation assay that we first used to identify BCGF II from DL 
supernatants uses the in vivo BCL~ tumor line originally characterized by Slavin 
and Strober (1 fi). The immunologically relevant biological properties of this line 
have been extensively studied by Knapp et al. (16) and by Isakson et al. (32). 
They have found that the BCL~ cells from BALB/c tumor-bearing animals are 
B cells expressing IgM and IgD. These cells can be induced to differentiate to 
Ig-secretion with either LPS, anti-Ig plus Con A-induced spleen cell supernatant, 
or various T  cell supernatants containing TRF or B cell differentiation factor, 
including supernatants from the C.C3.11.75  line, which contains (DL)TRF and 
(DL)BCGF (33). The low ratio of surface IgM/IgD and the functional similarity 
of BCL~ B cells to B cells from young (2-wk old) mice have prompted the proposal 
that the BCL~ B cells have the characteristics of immature B cells (32, 33). The 
results in this report are consistent with the view that BCL~ B cells are reflective 
of a  subset of normal B lymphocytes with a  unique response pattern.  Whether 
such a  subset  is  "immature" is  unclear since the correlation between surface 
phenotype of BCL~ and B cells from young mice is purely circumstantial evidence 
for immaturity and since different lineages of B cells could well become immu- 
nocompetent at different stages of B cell ontogeny. The BCL1 cells we harvest 
from the animal are found to be mostly in G~ phase, with few resting Go cells 
(Table I). 
The  possibility  that  BCGF  I  and  II  act  on  different cell  subsets  is  easily 
accommodated by  the  extensive  documentation  of B  cell  subpopulations.  In 
particular, mouse splenic B cells are known to contain two major populations of 
approximately equal  numerical size,  defined by  expression  of B  cell  surface 
markers Lyb-3, -5,  and -7.  B cells either express all three (most often termed 
Lyb-5  +) or fail to express any of them (Lyb-5-) (for a recent review see reference 
34). These two subsets are properly distinguished with the appropriate alloanti- 
sera. These antisera are in extremely limited supply, so most of what is known 
about  Lyb-5  + and  Lyb-5- B  cell  subsets  has  been inferred from experiments 
using mice with an X-linked defect found in CBA/N mice, which contain only 
Lyb5- B cells, compared with normal mice which have both Lyb-5  + and Lyb-5- 832  TWO  FUNCTIONALLY  DISTINCT  B  CELL  GROWTH  FACTORS 
cells.  It should be remembered that  the  Lyb-5- B cells present in the CBA/N 
mice as well as  other cells in  their  spleens may not be equivalent  to  those  in 
normal  mice  (35,  36).  In  particular,  since  they  may  be  more  immature,  the 
failure of B cells from xid mice to respond in a situation should not be interpreted 
as definitively showing that only Lyb-5  ÷ ceils are able to respond.  The experi- 
mental observation is that most lymphokine-drive proliferation and differentia- 
tion  in  in  vitro responses are  not seen  with  B  cells from xid mice,  except for 
antigen-specific responses using in vivo-primed cells (reviewed in reference 37). 
In  the  latter  case,  a  strict  requirement  for  direct  T-B  interaction  for  linked 
recognition  by T  cells of Ag and  B cell  I  region products has been seen (38). 
Recent experiments of Takatsu  (personal  communication)  suggest that  primed 
B cells from xid mice can indeed respond to TRF. B cells from xid mice do not 
proliferate  in  vitro  to  anti-~  plus  BCGF  I  or  to  BCGF  II  in  the  absence  of 
costimulation  (3). 4 However, our recent experiments (U. Staerz,  S.  Swain, and 
R. Dutton,  unpublished results) suggest that  B cells from mature xid mice can 
proliferate moderately in response to DXS plus BCGF II and that the addition 
of DXS, IL-2, and supernatants  containing (DL)TRF will produce sheep eryth- 
rocyte-specific plaque-forming cells. Thus it is likely that the Lyb-5- cells in xid 
mice  can  become  responsive  to  at  least  some  lymphokines  after  appropriate 
stimulation (polyclonal mitogens or in vivo priming). It will be necessary to isolate 
Lyb-5-  cells  from  normal  mice  to  determine  if  this  response  profile  is  also 
accurate for such cells and to gather further evidence to define whether the two 
subsets of B cells that respond, respectively, to anti-# plus BCGF I and DXS and 
BCGF II, correlate with Lyb-5  + and Lyb-5- subsets. 
Recent  studies  (11,  39)  have  described  two classes of BCGF activity in  the 
human  system that are made by T  cell clones which appear to synergize in the 
proliferative response of some B cells. One of these, with an apparent molecular 
weight  of "~17,000  synergizes  with  anti-Ig  and  appears  to  correlate  with  the 
BCGF I in the murine system. The second factor has a  50,000 mol wt and was 
active in  proliferation  of phytohemagglutinin-induced  colonies of B  cells (11) 
and of antiidiotype-stimulated BCLL cells (39). Further biochemical and biolog- 
ical experiments will be needed to determine if the murine BCGF II described 
herein is equivalent to the second human BCGF, but the circumstantial evidence 
suggests that  this  is a  serious possibility.  If this is so it might  be expected that 
murine  BCGF I  and  II  would both contribute  to the proliferation  of anti-Ig- 
induced B cells and that there is some suggestion that this prediction is born out 
as discussed above. The facts that the presence of B 15K 12 supernatants,  added 
late (48 h) in the response of anti-#- and BCGF I-stimulated cells, increases the 
cell recovery at day 5 (19), and that B 15K 12 contains BCGF II (3 and this report) 
are consistent with such a model. Taken together these data suggest a model in 
which BCGF I and II are growth factors of subsets of one lineage of B cells in 
different states of differentiation. However, they in no way rule out the possibility 
that  a  separate  lineage of B cells with  a  different response pattern  might  also 
exist and contribute to proliferation in some experimental situations. SWAIN ET  AL.  833 
Summary 
Several  previously described  B  cell  growth  factor  (BCGF)  activities from a 
number of mouse monoclonal T  cell sources were compared in different func- 
tional assays.  The  results  indicate that  there are  two distinct classes of BCGF 
defined  by  functional  activity  and  source.  BCGF  I,  whose  prototype  is 
(EL4)BCGF, synergized with anti-Ig in the proliferation of normal splenic B cells 
but had no activity when dextran sulfate (DXS), rather than anti-Ig, was used to 
costimulate the same source of B cells. BCGF I also failed to directly stimulate 
BCL1 tumor B cells. In contrast, BCGF II, whose prototype is (DL)BCGF, showed 
a  reciprocal  pattern  of  activity.  BCGF  II  failed  to  synergize  with  anti-Ig- 
costimulated  normal  B  cells  to  give  good  proliferative  responses.  Sources  of 
BCGF II also directly stimulated (no anti-Ig or DXS added) B cells of the BCLI 
tumor-carrying mice. These results suggest that the two BCGF may have activity 
on two subsets of B  cells that respond differentially to induction with the two 
polyclonal B cell activators, anti-Ig and DXS. The possibilities that these different 
patterns of response occur in separate  lineages of B  cells and/or  in B  cells in 
different states of differentiation is discussed. 
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